Oncotarget

Research Papers:

Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma

Wei Song, Kai Wang, Fu-ping Zhong, You-wen Fan, Lang Peng and Shu-bing Zou _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:81830-81838. https://doi.org/10.18632/oncotarget.13244

Metrics: PDF 1726 views  |   HTML 2048 views  |   ?  


Abstract

Wei Song1,*, Kai Wang1,*, Fu-ping Zhong1, You-wen Fan1, Lang Peng1, Shu-bing Zou1

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

*These authors have contributed equally to this work

Correspondence to:

Shu-bing Zou, email: [email protected]

Keywords: platelet to lymphocyte ratio (PLR), hepatocellular carcinoma, biomarker, prognosis, meta-analysis

Received: September 07, 2016     Accepted: October 17, 2016     Published: November 09, 2016

ABSTRACT

The platelet-to-lymphocyte ratio (PLR) is reported to be a prognostic factor in multiple malignancies. The aim of this study was to assess its prognostic value in hepatocellular carcinoma (HCC). We performed comprehensive searches of electronic databases for relevant studies. A total of eleven studies comprising 2,507 patients were included. Elevated PLR was significantly associated with poor overall survival (OS) (HR = 1.78; 95% CI = 1.36-2.34; P < 0.001) and disease-free survival (DFS)/recurrence-free survival (RFS) (HR = 1.82; 95% CI = 1.56-2.13; P < 0.001). The findings from most subgroup analyses were consistent with those from the overall analysis. In addition, a high PLR correlated with tumor size > 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion. We therefore conclude that elevated pretreatment PLR may be predicative of a poor prognosis in patients with HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13244